Welcome to the 1st Rare & Genetic Kidney Disease Drug Development Summit
The 1st Rare & Genetic Kidney Disease Drug Development conference is an unmissable opportunity to gain actionable insights into how the latest scientific research is being applied to pipeline progress. Connect with industry pioneers prioritizing the development of therapeutic treatments in PKD, IgA, FSGS, Alport Syndrome and more to understand how companies are navigating challenges in patient recruitment, regulatory barriers, and clinical setbacks to inform your drug discovery and development.
Unmissable highlights for 2021:
Investigate progress in identifying new diagnostic tools beyond creatinine, proteinuria, and total kidney volume with Tufts University School of Medicine to identify earlier biomarkers of disease progression and efficacy
Deep dive into applications of microRNA as a treatment for ADPKD, Alport Syndrome, FSGS, IgAN and more with Regulus Therapeutics to explore therapeutic strategies in using small non-coding RNAs and inform your pipeline development
Elucidate insights into disease modelling of genetic kidney diseases through stem cell-derived kidney organoids with the University of Manchester to understand transformative strategies for mimicking disease pathogenesis
Gain pivotal insights from Sanofi Genzyme into leveraging real-world evidence to achieve FDA’s full approval of a biologic and demonstrate long-term efficacy